Background {#Sec1}
==========

The current treatment guidelines of Crohn's disease (CD) include immunosuppressants, anti-inflammatory drugs, nutritional therapy and antibiotics. *Mycobacterium avium* subspecies *paratuberculosis* (MAP) was isolated from intestinal tissues, milk and blood samples from CD patients at a higher frequency than controls \[[@CR1]--[@CR3]\]. Other microorganisms have been associated with CD such as *Listeria monocytogenes, Staphylococcus aureus, Klebsiella pneumoniae* and enteropathogenic *Escherichia coli* \[[@CR4], [@CR5]\]. CD patients treated with prolonged combination of macrolide-based anti-mycobacterial regimens in randomized clinical trials have achieved reversal of CD symptoms \[[@CR6]\].

Most recently we evaluated the anti-microbial effect of three antibiotics regimen in the proprietary RHB-104 capsule formulation (RedHill Biopharma) in culture against 35 clinical MAP strains and other mycobacterial strains \[[@CR7]\]. We determined the MIC for individual, and dual and triple combinations of the three antibiotics and their solvents \[[@CR7]\] and have concluded that the triple combination of RHB-104 analog \[a mixture of individually dissolved 63.3 % Clarithromycin (CLA), 6.7 % Clofazimine (CLO) and 30 % Rifabutin (RIF)\] were more effective against MAP growth than when the cultures were treated with single or dual antibiotics dosages.

This study is focused on dissolving the proprietary RHB-104 capsule formulation in a solvent followed by determination of its MIC compared to RHB-104 analog against MAP and other microorganisms.

Results {#Sec2}
=======

In this study, we have successfully dissolved the proprietary RHB-104 capsule formulation in one compatible solvent. Due to proprietary ownership, RHB-104 capsule formulation solvent information can be requested directly from RedHill Biopharma. The MIC of the proprietary RHB-104 solvent against MAP and other microorganisms was at 12.5 % (v/v). The proprietary RHB-104 capsule formulation inhibitory effect on microorganisms with MIC ≤0.20 μg/mL was similar to RHB-104 analog (Fig. [1](#Fig1){ref-type="fig"}). However, the MIC for proprietary RHB-104 capsule formulation was at 2.0 μg/mL compared to 4.0 μg/mL for RHB-104 analog against MAP strain MS 137 from CD patient and *M. avium* strain *JF7* isolated from a HIV patient. The proprietary RHB-104 capsule formulation was more potent than RHB-104 analog against *M. fortuitum* subspecies *fortuitum* (MIC of 10 vs 15 μg/mL), *M. tuberculosis* strain HR237 (MIC of 5 vs 10 μg/mL), *M. smegmatis* ATCC 27199 (MIC of 0.5 vs 6 μg/mL), *S. aureus* ATCC 25923 (MIC of 0.125 vs 0.25 μg/mL), and *L. monocytogenes* ATCC 19112 (MIC of 0.25 vs 0.5 μg/mL). Interestingly, the MIC for CLA (63 % of the proprietary RHB-104 capsule formulation) against *S. aureus* and *L. monocytogenes* was at 1.5 μg/mL. Table [1](#Tab1){ref-type="table"} summarizes MIC values for both the proprietary RHB-104 capsule formulation and RHB-104 analog against several microorganisms used in this study. There was no significant inhibitory effect in culture on the growth of *K. pneumonia* (ATCC 13883) and plasmid-harboring *E. coli (*MIC \>40 μg/mL). The final concentration of solvents used to dissolve all the drugs in the study were ≤0.5 % (v/v) and had no effect on bacterial growth in cultures.Fig. 1Effect of the proprietary RHB-104 capsule formulation and RHB-104 analog on culture growth of MAP *MS 137, M. smegmatis, L. monocytogenes* and *S. aureus*. \* MIC level in μg/mL. \*\* The proprietary RHB-104 capsule formulation dissolved in one compatible solvent. \*\*\* RHB-104 analog (a mixture of individually dissolved 63.3 % Clarithromycin (CLA), 6.7 % Clofazimine (CLO) and 30 % Rifabutin (RIF), equal to  %composition in the proprietary RHB-104 capsule formulation)Table 1MIC of the proprietary RHB-104 capsule formulation and RHB-104 analogMicroorganismMinimum inhibitory concentration (μg/mL)CLA-CLO-RIF (RHB-104 analog)^a^Proprietary RHB-104 capsule formulation^b^*MAP MS 137*4.02.0*M. avium---JF7*4.02.0*M. fortuitum ss fortuitum*1510*M. tuberculosis* HR237105.0*M. smegmatis* ATCC 271996.00.125*S. aureus* ATCC 259230.250.125*L. monocytogenes* ATCC 191120.50.25*K. pneumonia* ATCC 13883\>40\>40Recombinant *E. coli*\>40\>40All cultures were performed in duplicates and have been repeated three times^a^RHB-104 analog where the 3 drugs dissolved individually were combined in one solution at their proprietary RHB-104 capsule formulation composition percentage^b^Proprietary RHB-104 capsule formulation was dissolved in one compatible solvent

Conclusion {#Sec3}
==========

The ability to evaluate the proprietary RHB-104 capsule formulation dissolved in one compatible solvent against broad spectrum of microorganisms demonstrated that this investigational single capsule formulation is more potent against *Mycobacteria* and other microorganisms associated with CD than previously determined. The study clearly concludes that the synergistic effect between CLA, CLO and RIF triple formulation in a single capsule is strong and therefore, favoring formulation-approach treatment. The data also suggests that the formulation approach might be used to re-evaluate antibiotics that have been declared as ineffective when used individually. The study strongly suggest that the proprietary RHB-104 capsule formulation should be more effective to eradicate MAP infection than regimens with multi-individualized antibiotics. Ultimately, one single capsule formulation treatment should enhance compliance and clinical outcome for CD patients.
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